Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Pharvaris (PHVS) to $41 from $37 and keeps an Overweight rating on the shares. With RAPIDe-3, the firm sees confirmation of a differentiated, rapid, and durable oral on-demand profile. The firm added that it expects investor focus to shift now to the planned NDA submission in 1H26 and the pivotal prophylactic data readout expected in 2H26.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
- Pharvaris price target raised to $38 from $28 at Leerink
- Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
- Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
- Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment